Table 1 Baseline characteristics of patients infused with ide-cel.

From: Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Characteristic

SOC Ide-cel with prior BCMA-TT (N = 50)

SOC Ide-cel without prior BCMA-TT (N = 153)

Median age (range)

66 (43–79)

63 (36–83)

Male gender, n (%)

33 (66)

89 (58)

Race/Ethnicity, n (%)

 White

33 (66)

117 (76)

 Black, Hispanic, Asian or other

17 (34)

36 (24)

ECOG PS, n (%)

 0–1

39 (81)

123 (83)

 2–4

9 (19)

25 (17)

R-ISS stage, n (%)

 I

4 (11)

28 (24)

 II

23 (62)

57 (48)

 III

10 (27)

33 (28)

Extramedullary disease, n (%)

25 (50)

85 (56)

High tumor burdena, n (%)

13 (30)

42 (29)

High-risk cytogenetics, n (%)

 Any high-riskb

17 (36)

42 (31)

 del(17p)

10 (21)

30 (22)

 t(4;14)*

11 (23)

10 (8)

 t(14;16)

1 (2)

6 (5)

Bridging therapy, n (%)

43 (86)

113 (74)

Median prior lines of therapy (range)*

9 (4–18)

6 (4–19)

Prior autologous SCT, n (%)

44 (88)

128 (84)

Prior allogeneic SCT, n (%)

2 (4)

10 (6.5)

Refractory status, n (%)

 Triple-class refractoryc

45 (90)

125 (82)

 Penta-drug refractory*d

31 (62)

57 (37)

Ide-cel dose (×106), median (range)

403.3 (154.1–454.0)

406.7 (253.4–456.4)

Ide-cel dose (×106), mean (SD)

392.4 (55.1)

399.3 (43.3)

 <400 × 106, n (%)

23 (46.0)

64 (42.1)

 ≥400 × 106, n (%)

27 (54.0)

88 (57.9)

  1. SOC standard of care, BCMA-TT BCMA targeted therapy, ECOG PS Eastern Cooperative Oncology Group Performance Status, R-ISS Revised International Staging System, SCT stem cell transplantation.
  2. *Statistically significant difference between cohorts, p < 0.05.
  3. aHigh tumor burden defined by ≥50% clonal plasma cells in pre-lymphodepletion chemotherapy bone marrow biopsy.
  4. bAs defined by the presence of del(17p), t(4;14) or t(14;16).
  5. cDefined as refractory to ≥1 immunomodulatory drug, ≥1 proteasome inhibitor, and ≥1 anti-CD38 monoclonal antibody.
  6. dPenta-refractory defined as refractory to ≥2 immunomodulatory drugs, ≥2 proteasome inhibitors, and ≥1 anti-CD38 monoclonal antibody.
Back to article page